Analysis for LH

📈 Growth & Financial Trajectory

Over the eight quarters, revenues rose from approximately $3.282B in 2024-Q3 to $3.731B in 2026-Q2, a start-to-end gain of about 13.7%. Net income climbed from about $143.6M to $299.1M, despite a mid-period dip to about $164.9M in 2025-Q2, then resuming a higher trajectory.

💰 Margins & Cash Flow

Gross profit margins remained strong around 27–30%; operating margins were in the 10–12% range, signaling stable profitability with modest leverage. Net cash flow from operating activities was positive in each tested quarter, notably around $445.5M in 2026-Q2, while investing and financing activities created sizable outflows, producing a net cash flow of -$840.6M in that quarter.

🛡️ Balance Sheet & Liquidity

Liquidity remains solid: current assets around $4.0–$4.6B vs current liabilities around $2.0–$2.6B, implying a healthy current ratio (~1.6–1.8). Equity sits near $8.0–$8.6B, with noncurrent liabilities typically in the lower to mid‑$6–7B range, supporting asset base and resilience.

⚠️ Key Drivers & Risks

• Drivers: Healthcare utilization and diagnostic testing volumes; lab automation and scalable operations.
• Risks: Reimbursement/rate pressure; exposure to healthcare demand cycles and regulatory changes.